Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including:
- First-in-human study timing
- Remaining steps to first-in-human study
- Q&A session
Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!
https://youtu.be/NmBiGLHMhFo
Dear Investors, I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance. One month following cataract surgery and
Ocumetics Director and CEO, Dean Burns covers important updates on our first-in-human (FIH) study and what lies ahead. Topics include: Encouraging outcomes from initial surgeries Next steps to complete the FIH study Live Q&A session with Dean Burns https://youtu.be/rWQnOaq6sVE
This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed. I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief
Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens. What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of
